Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The porphyrias: advances in diagnosis and treatment.
[erythropoietic protoporphyria]
The
inborn
errors
of
heme
biosynthesis
,
the
porphyrias
,
are
8
genetically
distinct
metabolic
disorders
that
can
be
classified
as
"
acute
hepatic
,
"
"
hepatic
cutaneous
,
"
and
"
erythropoietic
cutaneous
"
diseases
.
Recent
advances
in
understanding
their
pathogenesis
and
molecular
genetic
heterogeneity
have
led
to
improved
diagnosis
and
treatment
.
These
advances
include
DNA-based
diagnoses
for
all
the
porphyrias
,
new
understanding
of
the
pathogenesis
of
the
acute
hepatic
porphyrias
,
identification
of
the
iron
overload-induced
inhibitor
of
hepatic
uroporphyrin
decarboxylase
activity
that
causes
the
most
common
porphyria
,
porphyria
cutanea
tarda
,
the
identification
of
an
X-
linked
form
of
erythropoietic
protoporphyria
due
to
gain-of-function
mutations
in
erythroid-
specific
5
-
aminolevulinate
synthase
(
ALAS
2
)
,
and
new
and
experimental
treatments
for
the
erythropoietic
porphyrias
.
Knowledge
of
these
advances
is
relevant
for
hematologists
because
they
administer
the
hematin
infusions
to
treat
the
acute
attacks
in
patients
with
the
acute
hepatic
porphyrias
,
perform
the
chronic
phlebotomies
to
reduce
the
iron
overload
and
clear
the
dermatologic
lesions
in
porphyria
cutanea
tarda
,
and
diagnose
and
treat
the
erythropoietic
porphyrias
,
including
chronic
erythrocyte
transfusions
,
bone
marrow
or
hematopoietic
stem
cell
transplants
,
and
experimental
pharmacologic
chaperone
and
stem
cell
gene
therapies
for
congenital
erythropoietic
protoporphyria
.
These
developments
are
reviewed
to
update
hematologists
on
the
latest
advances
in
these
diverse
disorders
.
Diseases
Validation
Diseases presenting
"acute attacks in patients with the acute hepatic porphyrias"
symptom
erythropoietic protoporphyria
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom